Advice

Following a full submission

Anagrelide (Xagrid) is not recommended for use within NHS Scotland for the reduction of elevated platelet counts in ‘at risk’ patients with essential thrombocythaemia who are intolerant of their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. The cost effectiveness of anagrelide has not been demonstrated.

The licence holder has indicated their decision to resubmit

Download detailed advice48KB (PDF)

Download

Medicine details

Medicine name:
Anagrelide 0.5mg capsule (Xagrid®)
SMC ID:
163/05
Indication:
Reduction of elevated platelet counts in 'at risk' patients with essential thrombocythaemia
Pharmaceutical company
Shire Pharmaceuticals
BNF chapter
Nutrition and blood
Submission type
Full
Status
Not recommended
Date advice published
09 May 2005